Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Table 1

Characteristics of patients and healthy volunteers (HVs).

Group	Gender; F/M	Age (years); Mean ± SD	Disease duration (years)**; Mean ± SD	EDSS**; Mean ± SD	EDSS before Nat. treatment; Mean ± SD	Annualized relapse rate during last 3 years; Mean ± SD	Annualized relapse rate on Nat. treatment; Mean ± SD	Number of relapse free patients on Nat. treatment
HV (𝑛=14)	10/4	39.6±10.1	na	na	na	na	na	na
Untreated (𝑛=14)	10/4	46.9±9.4^∗	9.64±5.77	2.07±1.08	na	0.45±0.82	na	na
Nat. treated (𝑛=14)	10/4	39.4±8.9	8.42±4.83	3.03±1.51	3.53±1.39	0.83±0.44^∗∗∗	0.35±0.40	6/14

na: not applicable.
*Untreated RRMS patients are older than HVs (n.s.) and natalizumab (Nat.) treated patients (𝑃<0.05).
**At the sampling time.
***Before natalizumab (Nat.) treatment.